Risk of metastatic disease on 68-Ga‐PSMA PET/CT scan for primary staging of 1253 men with PCa

The aim of the work in this article is to determine the number of men with 68Ga‐prostate‐specific membrane antigen PET/CT avid metastasis at diagnosis. Read the article here: https://onlinelibrary.wiley.com/doi/10.1111/bju.14774

A recent trial published in BJU International has confirmed the use of PSMA Pet / CT scanning as an effective diagnostic tool for primary staging of Prostate Cancer.

The trial was conducted on 1253 consecutive men referred by urologists or radiation oncologists to a tertiary referral centre for Ga‐PSMA PET/CT scan for staging at the initial diagnosis of prostate cancer between July 2014 and June 2018.

A collaboration between Urologists, Radiologists, and PET/Nuclear Medicine Specialists in France and Australia, including Assoc. Professor David Wong, who is a Radiologist and PET/Nuclear Medicine Specialist at Wesley Medical Imaging, Brisbane.

Wesley Medical Imaging (WMI) was the first private facility to offer a PET service in Australia, and is the leading provider of PET imaging. WMI also pioneered Ga-68 PSMA PET scanning for prostate cancer.

Six months after WMI began performing PSMA PET/CT scans, the average number of monthly NMBS plummeted by almost 50% in favour of PSMA PET/CT. Five years later the rate of NMBS used for staging prostate cancer had dropped by 95% – showing in almost all cases urologists were choosing PSMA PET/CT for their patients instead.

The latest trial confirms that PSMA Pet / CT scanning is working.

Read more about Wesley Medical Imaging’s pioneering Prostate Cancer research and treatment.